Inbiomotion: Predicting bone metastasis

Startup

SOBRE INBIOMOTION

      
Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2010 with the goal of developing biomarkers that predict bone metastasis to improve the quality of life of cancer patients. The company is a spin out of the IRB Barcelona and ICREA research institutions and was founded by Dr. Roger Gomis.

Our activities are focused on the development of a diagnostic assay based on a selective single gene/protein biomarker that predicts those patients at risk of suffering bone-specific metastases from primary tumors. The exquisite selectivity of our lead biomarker provides the grounds for the development of companion diagnostics – selecting patients that will benefit from the preventive use of anti-bone metastatic drugs, and making a step forward in the clinical standard of care using personalized medicine.
    
Organization founded in Spain.

COMPONENTES DEL EQUIPO

SECTORES - INDUSTRIA

UBICACIONES

COMPARTIR PERFIL

Este perfil tiene una gran apariencia, ¿quieres compatirlo con todos?
PRINCIPIANTE
AVANZADO
PROFESIONAL

Esta web usa cookies para que podamos entender cómo se utiliza el sitio. Si sigues navegando asumiremos que te parece bien. Si quieres utilizar este sitio sin cookies o si quieres saber más, puedes hacerlo aquí .